Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Dose Escalation Study to Assess the Safety and Tolerability of AB126 Neural Exosomes Intravenous Injection in Patients With Moderate to Severe Acute Ischemic Stroke Following Endovascular Therapy and Limited Neurological Improvement

NCT07813130 is registered in ClinicalTrials.gov with Aruna Bio, Inc. as lead sponsor.

NCT NCT07813130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07813130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Dose Escalation Study to Assess the Safety and Tolerability of AB126 Neural Exosomes Intravenous Injection in Patients With Moderate to Severe Acute Ischemic Stroke Following Endovascular Therapy and Limited Neurological Improvement
Lead sponsor
Aruna Bio, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2029
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke